Purple Biotech To Present New Preclinical Data From CAPTN-3 Platform Of Conditionally Activated Tri-Specific Antibodies At ESMO-IO 2025 Annual Congress

New data showcase the versatility and anti-tumor activity of the CAPTN-3 platform and its unique multi-arm design in treatment-resistant cancers    

REHOVOT, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced that it will present new preclinical data from its CAPTN-3 platform of conditionally activated tri-specific antibodies at the upcoming European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress being held from December 10–12, 2025, in London, United Kingdom.